With Continuous Failure Active Biotech Regains Global Rights for Laquinimod from Teva

 With Continuous Failure Active Biotech Regains Global Rights for Laquinimod from Teva

With Continuous Failure Active Biotech Regains Global Rights for Laquinimod from Teva

Shots:

  • Teva was assessing laquinimod since 2007, globally the drug completed three P-III studies ALLEGRO, BRAVO and CONCERTO in rrMS, P-II study ARPEGGIO in primary progressive MS and single P-II LEGATO-HD trial in Huntington’s Disease(HD)
  • The P-II LEGATO-HD trial in HD fails to meet 1EP@12 mos, additionally in Dec 2017, P-II POC study of laquinimod didn’t meet 1EP and 2EP in Primary Progressive MS
  • Laquinimod a qd PO selective aryl hydrocarbon receptor (AhR), for treatment of MS and HD and is also being studied for Crohn’s disease and Lupus

Click here to read full press release/ article | Ref: Active Biotech | Image: Affarsvarlde

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post